Patients with moderately severe or severe heart failure often experience cardiac decompensation, which manifests itself in an increase of pulmonary arterial pressure long before the classic symptoms (shortness of breath, water retention, etc.) arise. As a result, hospitalisation and a deterioration in quality of life occur repeatedly. The systematic review addressed the question to what extent an implant for measuring pulmonary arterial pressure (CardioMEMS™ HF System) is superior to standard monitoring programmes. The evidence showed a clinical benefit in favour of the intervention in terms of hospitalisation rates and quality of life. The number of serious adverse events was found to be low. A randomised controlled trial of the CardioMEMS™ HF system is currently underway with a total of 3,600 participants and is expected to be completed by mid 2023.